Dicerna Pharmaceuticals Revenue

Pharmaceutical Manufacturing • Lexington, Massachusetts, United States • 51-100 Employees

Dicerna Pharmaceuticals revenue & valuation

Annual revenue	$192,800,000
Revenue per employee	$2,074,000
Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues	$617,000,000
Total funding	$200,000,000

Key Contacts at Dicerna Pharmaceuticals

Christina Nacos

Executive Director, Manufacturing

Ayni N. Strang

Senior Director, Facilities Operations

Robin Currie

Associate Director, Product Quality

Miao Yu

Senior Director Of Biostatistics

Shaun Dunphy

Director Of Accounting

Shama Tichkule

Associate Director

Amber Beaudry

Senior Director Of Nonclinical Ba And Adme

Elizabeth Hetherman

Director, Finance And Fp&A Lead

Tim Larson

Director Of Api Manufacturing

Deborah Twombly

Associate Director, Clinical Quality Assurance

Company overview

Headquarters	33 Hayden Ave, Lexington, Massachusetts 02421, US
Phone number	+16099875800
Websites	novonordisk-us.com dicerna.com
NAICS	3254
SIC	283
Founded	2007
Employees	51-100
Socials

Dicerna Pharmaceuticals Email Formats

Dicerna Pharmaceuticals uses 4 email formats. The most common is {first name}{last name} (e.g., johndoe@dicerna.com), used 56.1% of the time.

Format	Example	Percentage
{first name}{last name}	johndoe@dicerna.com	56.1%
{first initial}{last name}	jdoe@dicerna.com	36.6%
{last name}{last name}	doedoe@dicerna.com	4.9%
{f2}{last name}	{f2}doe@dicerna.com	2.4%

About Dicerna Pharmaceuticals

Dicerna, a wholly owned subsidiary of Novo Nordisk, is focused on driving innovation in RNAi (ribonucleic acid interference) to selectively target and silence genes that cause or contribute to disease. Using our proprietary GalXC™ and GalXC-Plus™ RNAi technologies, we discover and develop innovative RNAi-based therapies with the potential to treat both rare and more prevalent diseases. By silencing disease-causing genes, our GalXC platform has the potential to address conditions that are difficult to treat with other modalities. Initially focused on disease-causing genes in the liver, we have continued to innovate and are exploring new applications of our RNAi technology with GalXC-Plus, which expands on the functionality and application of our flagship liver-targeted GalXC technology to tissues and cell types outside the liver with the potential to treat diseases across multiple therapeutic areas. Our team brings together talented experts across the fields of biology, chemistry, clinical science, medicine and more. With decades of scientific and technical experience focused on RNAi technology, we have the knowledge and experience needed to discover and develop therapies for patients with serious unmet medical needs. Between our own pipeline of core discovery and clinical candidates and those developed through collaborative relationships with some of the world’s leading pharmaceutical companies, we have generated more than 20 active discovery, preclinical or clinical proprietary and collaborative programs focused on rare, cardiometabolic, viral, chronic liver and complement-mediated diseases, as well as neurodegenerative diseases and pain.

Employees by Management Level

Total employees: 51-100

Seniority

Employees

Entry

Manager

Director

Employees by Department

Dicerna Pharmaceuticals has 33 employees across 9 departments.

Departments

Number of employees

Funding Data

Explore Dicerna Pharmaceuticals's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2018-10-08	14	$200,000,000

Funding Insights

$200,000,000

Total funding amount

$200,000,000

Most recent funding amount

Number of funding rounds

Dicerna Pharmaceuticals Tech Stack

Discover the technologies and tools that power Dicerna Pharmaceuticals's digital infrastructure, from frameworks to analytics platforms.

reCAPTCHA

Security

Akamai mPulse

RUM

HTTP/2

Miscellaneous

Adobe Experience Manager

CMS

Axios

JavaScript libraries

Hotjar

Analytics

jQuery

JavaScript libraries

Google Ads

Advertising

Akamai

CDN

HSTS

Security

Adobe Experience Platform Launch

Tag managers

Google Analytics

Analytics

Frequently asked questions

Dicerna Pharmaceuticals is located in Lexington, Massachusetts, US.

You can reach Dicerna Pharmaceuticals at +16099875800.

Dicerna Pharmaceuticals generates an estimated annual revenue of $192,800,000. This revenue figure reflects the company's market position and business performance in its industry.

Dicerna Pharmaceuticals has an estimated valuation of $617,000,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Dicerna Pharmaceuticals was founded in 2007, making it 19 years old. The company has established itself as a significant player in its industry over this time.

Dicerna Pharmaceuticals has approximately 51-100 employees. The company continues to grow its workforce to support its business operations and expansion.

Dicerna Pharmaceuticals has raised a total of $200,000,000 across 1 funding rounds. This investment has helped the company grow and expand its operations.